Sunshine Biopharma Q3 EPS $(0.04) Beats $(0.06) Estimate, Sales $5.60M Miss $6.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sunshine Biopharma (NASDAQ:SBFM) reported Q3 earnings with an EPS of $(0.04), surpassing the $(0.06) estimate, marking a 50% improvement from last year's $(0.08). However, sales of $5.60M fell short of the $6.00M estimate, despite being a significant increase from the previous year's $132.81K.
November 13, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sunshine Biopharma reported better-than-expected Q3 EPS but missed revenue estimates, showing significant year-over-year growth.
While the EPS beat may provide a positive sentiment, the miss on revenue estimates could temper investor enthusiasm. The substantial year-over-year growth in sales indicates strong business development, which may balance the short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100